louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04955002: Food Choice, Psychological Bias, and Genetic Predisposition
Official title: Food Choice, Psychological Bias, and Genetic Predisposition
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Food Preferences
Genetic Predisposition
Psychological
Lead sponsor: Oxford Brookes University
Sponsor class: OTHER
Collaborators: name: St. Mary's University, Twickenham
First posted: 2021-07-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male or female, adult (18+), UK-based

Brief summary: This project aims to assess if food choice is impacted by loss aversion (LA), and if this differs based on genetic predisposition to LA, in a UK healthy cohort.

Detailed description: Food choice, defined as how individuals decide on what to buy and eat, involves the acceptance and rejection of specific foods. Food customisation is becoming more common amongst food retailers, allowing customers to alter their meals to their preferences by removing or adding items. Today, food choice is viewed as more complex, food choices are not just dictated by taste but nutritional quality, allergens, and habits. For example, the framework provided for food customisation (e.g. pizza with toppings or a build you own pizza) and the perceived 'healthiness' of food items (e.g. the pizza toppings) can alter food choice. Psychological reasoning, the process by which humans make decisions by drawing conclusions can play a role in food choice; however, humans can possess a psychological bias leading to illogical decision making. Genetics can too play a role in decision making resulting in predetermined influence on food choice. This research wishes to determine if individual's genetics can affect their food choices by researching psychological biases to food choices.

Eligibility criteria: Inclusion Criteria:

* Healthy (no known health condition)
* 18 + years of age
* UK based

Exclusion Criteria:

* Vegetarian
* Vegan
* Other dietary pattern that restricts the consumption of animal products

Primary outcomes:
measure: Frequency of food items remaining
timeFrame: December 2021
measure: Frequency of healthy and unhealthy items remaining
timeFrame: December 2021
measure: Loss aversion score
timeFrame: December 2021
measure: Genotype: BDNF Val/Met (rs6265), and DRD2 ANNKK1 Taq1a/ANKK1 (rs1800497)
timeFrame: December 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: Oxford Brookes University
Study officials:
References:
Clinical trial NCT05203302: Novel Coding Strategies for Children With Cochlear Implants
Official title: Novel Coding Strategies for Children With Cochlear Implants
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Deafness
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2022-01-24
Enrollment: 190
Sex: ALL
Minimum age (years): 6
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to understand performance with a cochlear implant. The long-term goals of this research are to improve sound perception with cochlear implants and to better understand the functioning of the auditory system. Information from individuals with and without cochlear implants will be compared.

Detailed description: The overall objectives of this research are to 1) gain a better understanding of fundamental psychophysical abilities with electrical stimulation as a function of age (child vs adult), age at onset of deafness (pre- vs post-lingual), and acoustic hearing (normal vs limited or residual); and 2) determine whether manipulations in CI coding strategies will improve psychophysical and speech recognition outcomes for early implanted children. This work is expected to provide new insights into the corresponding improvements in perceptual outcomes to these newer strategies have been modest at best and performance has begun to level off.

Eligibility criteria: Inclusion Criteria:

* Be 7 years of age or older and pre-lingually implanted with a cochlear implant (before the age of 2 years), have aided residual hearing, or have normal hearing.
* Be ages 18 or older and post-lingually implanted or have normal hearing.
* Be ages 18-35 and pre-lingually implanted.

Exclusion Criteria:

* Any child implanted post-lingually

Primary outcomes:
measure: Change in loudness growth in Cochlear Implant participants
timeFrame: Baseline Visit (Day 1) , Visit week 10
measure: Change in temporal resolution in Cochlear implant participants
timeFrame: Baseline Visit (Day 1) , Visit week 10
measure: Change in spectral resolution in Cochlear implant participants
timeFrame: Baseline Visit (Day 1) , Visit week 10
measure: Difference in performance between the reduced channel map and the full map
timeFrame: Baseline Visit (Day 1) , Visit week 10
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: David M Landsberger, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03193502: Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
Official title: Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Portal Vein Thrombosis
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2017-06-20
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: -Rivaroxaban is factor Xa inhibitor

Detailed description: PVT is a common complication of liver cirrhosis

Eligibility criteria: Inclusion Criteria:

* Acute PVT

Exclusion Criteria:

* Malignant PVT
* Bleeding disorders

Primary outcomes:
measure: Number of patients with recanalized portal vein
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Tropical medicine dept.-Tanta university hospital
Study officials:
affiliation: Hepatology unit - Zagazig University
name: Amr Hanafy, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Radiology Dept - Zagazig University
name: Mohamed Basha, Consultant
role: STUDY_DIRECTOR
affiliation: Hepatology - Gastroenterology - Tanta University
name: Sherief Abd-elsalam, consultant
role: STUDY_CHAIR
References:
Clinical trial NCT05759702: Correlation Between Body Mass Index, Manual Dexterity and Handgrip Strength in School Aged Children
Official title: Correlation Between Body Mass Index, Manual Dexterity and Handgrip Strength in School Aged Children
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Body Mass Index,Manual Dexterity,Handgrip Strength,School Aged Children
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-03-08
Enrollment: 85
Sex: ALL
Minimum age (years): 9
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: The purpose of current study is to investigate the relation between body mass index, manual dexterity and handgrip strength in school aged children having normal weight, overweight and obesity.

Detailed description: The study targeted the normal weight, overweight and obese students (9-11) from both sexes will be selected from governmental primary schools.

Study design:

Cross sectional observational correlational study.

A. Inclusion criteria:

1. The students' age ranges from 9 to 11 years.
2. Normal weight, Overweight and obese students were included
3. both boys and girl will be included.

B. Exclusion criteria:

The students will be excluded from the study if they have one of the following:

1. Congenital abnormalities or medical conditions, which may affect the study.
2. Musculoskeletal problems such as previous or recent orthopedic surgery, fractures, prostheses, inflammation of the fingers, arms, or shoulder.
3. Visual or hearing defects.
4. Motor, behavioral, or neurologic disorders and learning disabilities.

   * All children will be assessed using: the Standard weight and height measuring scale to determine their BMI.
   * Assessment of manual dexterity will be carried out by using the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2) (Bruininks and Bruininks, 2005).
   * Handgrip strength will be assessed by hand dynamometer.

Eligibility criteria: Inclusion Criteria:

1. The students' age will range from 9 to 11 years.
2. Normal weight, Overweight and obese students including both boys and girl.

Exclusion Criteria:

* The students will be excluded from the study if they have one of the following:

  1. Congenital abnormalities or medical conditions, which may affect the study.
  2. Musculoskeletal problems such as previous or recent orthopedic surgery, fractures, prostheses, inflammation of the fingers, arms, or shoulder.
  3. Visual or hearing defects.
  4. Motor, behavioral, or neurologic disorders and learning disabilities.

Primary outcomes:
measure: assessment of manual dexterity
timeFrame: Baseline-45min for each participant
measure: • Handgrip strength
timeFrame: Baseline-45min for each participant
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
affiliation: Cairo University
name: wessam os sayed
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02266602: Intraoperative Radiation Therapy in Early Stage Breast Cancer
Official title: Intra-Operative Radiotherapy After Breast Conserving Therapy in the Treatment of in Situ and Early Stage Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: IORT
Breast Cancer
Lead sponsor: Benaroya Research Institute
Sponsor class: OTHER
First posted: 2014-10-17
Enrollment: 500
Sex: FEMALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Single arm study to assess the effectiveness of single dose intraoperative radiation therapy in patient with in situ and early stage breast cancer.

Detailed description: The purpose of this clinical study is to assess the effectiveness of IORT, using an electronic brachytherapy system, in patients with limited-volume in situ and early stage breast cancer, with endpoints of:

* Local recurrence in early stage breast cancer patients treated with IORT.
* Toxicity associated with IORT.
* Long-term disease-specific and overall survival
* Cosmetic results using the Harvard Scale at start and follow-up periods in patients treated with IORT.
* Quality of life in patients treated with IORT.
* Health care costs associated with IORT.

Eligibility criteria: Inclusion Criteria:

General Inclusion Criteria

1. Age ≥ 45 years.
2. Clinical stage Tis, T1, T2 (≤ 3cm), N0, M0 (AJCC Classification).
3. Invasive ductal or lobular carcinoma, DCIS and/ or pleomorphic lobular carcinoma in situ.

Exclusion Criteria:

1. Scleroderma, systemic sclerosis and active lupus.
2. Participation in an investigational drug or device study.
3. Previous ipsilateral radiation to the thorax or breast.
4. Multifocal breast cancer.
5. Pregnant patients.
6. Patient not competent to provide informed consent.
7. Neoadjuvant systemic therapy.
8. Lymphovascular invasion on biopsy pathology

Primary outcomes:
measure: Local Disease Relapse
timeFrame: 10 years
Secondary outcomes:
measure: Disease specific and overall survival
timeFrame: 10 years
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
Study officials:
affiliation: Virginia Mason Medical Center
name: Janie Grumley, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02001402: Chinese Health Investigation of Nurse Aging
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lipid Depletion
Excessive Physical Exercise, Unspecified
Menopausal Syndrome
Keywords: climacteric symptoms ; nurse ;
intervention;follow-up
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
First posted: 2013-12-04
Enrollment: 2
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: About 2000 nurese aged 40-55 living in peking will be investigated.We will measure the symptoms of perimenopausal syndrome by kupperman index、HRQOL（health -related quality of life) to evaluate the severity of menopausal syndrome and quality of life.We choose nurses whose KMI is above 15 and divided them into intervention group and control group.In intervention group,we give them health education and exercise intervention.

Brief summary: A follow-up intervention for the climacteric symptoms of nurses in Peking

Detailed description: As we all know,hormone replacement therapy (HRT) is the main therapy to climacteric symptoms.But HRT has also some disadvantages including breast cancer,cardiovascular disease and so on, especially long period of HRT. It makes us to find the non-hormone therapy. So we want to investigate the exercise on the effect of climacteric symptoms.Doing exercise is helpful for avoiding and treating many disease,including climacteric symptoms.In our previous research,we found that playing exercise can treat moderate climacteric symptoms.

Eligibility criteria: Inclusion Criteria:

* they are nurse ,aged40-55, lived in peking ,who are among perimenopausal women.

Exclusion Criteria:

-

Primary outcomes:
measure: the number of KMI
timeFrame: up to 2 years
Secondary outcomes:
measure: blood lipid
timeFrame: up to 2 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05315102: Effects of Intensive Chiropractic Care to Usual Care for Children With Cerebral Palsy.
Official title: To Investigate the Effects of Three Weeks of Intensive Chiropractic Care When Added to Usual Care for Children With Cerebral Palsy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebral Palsy
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-04-07
Enrollment: 39
Sex: ALL
Minimum age (years): 2
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Research
Primary purpose: TREATMENT

Brief summary: To determine the effects of chiropractic care on spasticity, functional outcomes and quality of life in spastic cerebral Palsy children.


Eligibility criteria: Inclusion Criteria:

Participants will be recruited into the study according to the following criteria.

* Both gender (Male and Female).
* Age between 2 to 15 years.
* Spastic Cerebral Palsy children.

Exclusion Criteria:

Participants will be excluded from the study according to the following criteria.

* Cerebral Palsy children due to Traumatic Brain Injury.
* Patients having cognitive impairments.
* Patients having associated Neurological Pathologies.
* Patients who are unable to follow treatment plan.

Primary outcomes:
measure: Gross Motor Function Measure
timeFrame: 3 weeks
measure: Trunk Control Measurement Scale (TCMS)
timeFrame: 3 weeks
measure: Melbourne Assessment of Unilateral Upper Limb Function (MUUL)
timeFrame: 3 weeks
measure: Canadian Occupation Performance Measure (COPM)
timeFrame: 3 weeks
measure: Cerebral Palsy Quality Of Life scale (CP-QOL)
timeFrame: 3 weeks
measure: Smartphone app for gait and Balance Assessment
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: National Institute of rehabilitation medicine.
state: Federal
Study officials:
affiliation: Riphah International University
name: IMRAN AMJAD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06153602: Effectiveness of Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in TURP Surgery
Official title: Effectiveness of Intrathecal Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in Patients Undergoing Transurethral Resection of the Prostate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Transurethral Resection of Prostate
Keywords: Anesthesia, Spinal
Pain, Postoperative
Nalbuphine
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2023-12-01
Enrollment: 80
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare pain after surgery in patients undergoing Transurethral Resection of Prostate. The main question it aims to answer are: Intrathecal nalbuphine as an adjuvant to local anesthetic will better provide pain relief after TURP surgery.

Participants will be given a combination of nalbuphine and local anesthetic when getting a spinal block. Researchers will compare control group, given look-alike solution that contains no active drug to see if nalbuphine will better provide pain relief after surgery.

Detailed description: This study aims to evaluate the efficacy and side effects of nalbuphine, with the goal of providing anesthesiologists with evidence-based guidance for selecting the most appropriate pharmacological agents for their patients.

Participants will be given a combination of nalbuphine and local anesthetic when getting a spinal block. Researchers will compare control group, given look-alike solution that contains no active drug to see if nalbuphine will better provide pain relief after surgery.

Eligibility criteria: Inclusion Criteria:

* Patients scheduled for Transurethral Resection of Prostate under spinal anesthesia
* American Society of Anesthesiologists (ASA) physical status I-III

Exclusion Criteria:

* Allergy to study medications or hypersensitive to local anesthetics
* Contraindicated for neuraxial anesthesia
* Inability to self-report pain
* Chronic opioid used

Primary outcomes:
measure: VAS Pain score
timeFrame: 12 hour postoperative
Secondary outcomes:
measure: VAS Pain score
timeFrame: 24 hour postoperative
measure: Time to first rescue analgesia
timeFrame: 24 hour postoperative
measure: Total analgesics consumption
timeFrame: 24 hour postoperative
measure: Nausea and vomiting incidence
timeFrame: 24 hour postoperative
measure: Pruritus incidence
timeFrame: 24 hour postoperative
measure: Sedation score(Ramsay sedation scale)
timeFrame: 24 hour postoperative
Other outcomes:
Locations:
city: Pathum Wan
country: Thailand
facility: Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University
state: Bangkok
Study officials:
affiliation: Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
name: Piyatida Pirasut, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01278602: R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma
Official title: A Multi-center Phase II Study of R-ESHAP Followed by Autologous Transplantation as Salvage Treatment for Patients With Refractory or Relapsed Diffuse Large B-cell Lymphoma.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Diffuse Large B-cell Lymphoma
Keywords: Diffuse large B-cell lymphoma
Chemotherapy
R-ESHAP
Autologous stem cell transplantation
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2011-01-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of study is to prove R-ESHAP regimen followed by autologous stem cell transplantation as salvage treatment in patients with refractory or relapsed diffuse large B-cell lymphoma is effective.

Detailed description: The standard treatment in patients with refractory or relapsed diffuse large B-cell lymphoma is salvage chemotherapy followed by autologous transplantation for responsive patients. However, the standard of salvage chemotherapy remains uncertain. This study is to evaluate the efficacy and safety of R-ESHAP regimen in a multi-center basis.

Eligibility criteria: Inclusion Criteria:

* Age range: 18-65 years old
* Histological confirmed diffuse large B-cell lymphoma
* Refractory or first relapsed disease
* Prior anthracycline exposure
* Measurable disease
* ECOG performance status 0-1
* Life expectancy of more than 3 months
* Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧90g/L
* Liver function: total bilirubin, ALT and AST \<1.5×UNL
* Renal function: Cr\<1.5×UNL, CCR≧50ml/min
* No contraindication for transplantation

Exclusion Criteria:

* Evidence of CNS and bone marrow involvement
* More than 1 type of chemotherapy regimens exposure
* High level of HBV DNA
* Contraindication of high-dose methylprednisolone
* Pregnant or lactating women
* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
* History of allergic reaction/hypersensitivity to rituximab
* Significant active infection

Primary outcomes:
measure: Overall response rate
timeFrame: 6 weeks
Secondary outcomes:
measure: 3-year progression-free survival rate
timeFrame: 3 years
measure: 3-y overall survival rate
timeFrame: 3 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
Study officials:
affiliation: Fudan University
name: Ye Guo, MD
role: PRINCIPAL_INVESTIGATOR
References: